- Home
- MATV vs REPL Comparison
MATV vs REPL Comparison
Compare MATV & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MATV
- REPL
- Stock Information
- Founded
- MATV 1995
- REPL 2015
- Country
- MATV United States
- REPL United States
- Employees
- MATV N/A
- REPL N/A
- Industry
- MATV Paper
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- MATV Basic Materials
- REPL Health Care
- Exchange
- MATV Nasdaq
- REPL Nasdaq
- Market Cap
- MATV 671.4M
- REPL 547.0M
- IPO Year
- MATV 1995
- REPL 2018
- Fundamental
- Price
- MATV $11.55
- REPL $9.58
- Analyst Decision
- MATV Strong Buy
- REPL Buy
- Analyst Count
- MATV 1
- REPL 9
- Target Price
- MATV $10.00
- REPL $10.71
- AVG Volume (30 Days)
- MATV 381.9K
- REPL 8.6M
- Earning Date
- MATV 11-05-2025
- REPL 11-11-2025
- Dividend Yield
- MATV 3.46%
- REPL N/A
- EPS Growth
- MATV N/A
- REPL N/A
- EPS
- MATV N/A
- REPL N/A
- Revenue
- MATV $1,967,300,000.00
- REPL N/A
- Revenue This Year
- MATV $3.68
- REPL N/A
- Revenue Next Year
- MATV $2.82
- REPL N/A
- P/E Ratio
- MATV N/A
- REPL N/A
- Revenue Growth
- MATV N/A
- REPL N/A
- 52 Week Low
- MATV $4.34
- REPL $2.68
- 52 Week High
- MATV $17.47
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- MATV 57.21
- REPL 76.86
- Support Level
- MATV $10.41
- REPL $7.69
- Resistance Level
- MATV $11.29
- REPL $9.03
- Average True Range (ATR)
- MATV 0.48
- REPL 0.55
- MACD
- MATV 0.08
- REPL 0.54
- Stochastic Oscillator
- MATV 88.21
- REPL 88.16
About MATV Mativ Holdings Inc.
Mativ Holdings Inc is a diversified producer of premium specialty papers and resin-based products. It manufactures and sells paper and reconstituted tobacco products to the tobacco industry as well as specialized paper products. The company operates in two segments namely Advanced Materials and Structures, which manufactures resin-based products used in specialty applications in the filtration, infrastructure and construction, transportation, industrial, and medical end-markets, and Engineered Papers, which produces cigarette papers and reconstituted tobacco products for cigarette and cigar manufacturers, as well as various other non-tobacco paper products.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.